Psoriasis | Access and Reimbursement | US | 2021

Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics market, but the approval of novel, effective therapies has started changing the landscape as newer biologics gain greater acceptance from treating physicians. Novartis’s IL-17 inhibitor Cosentyx and Amgen’s oral phosphodiesterase (PDE)-4 inhibitor Otezla have successfully carved out space in the treatment algorithm. More-effective biologics—AbbVie’s Skyrizi, Janssen’s Tremfya, and Eli Lilly’s Taltz—are threatening TNF-α inhibitors’ first-line dominance. Given the recent entry of biosimilars and the late-phase development of an IL-17 A/F dual inhibitor, an oral tyrosine kinase 2 (TYK2) inhibitor, and two novel topical therapies, marketers of psoriasis therapies must learn how to navigate this increasingly competitive market.

QUESTIONS ANSWERED

• What are the current patient-share leaders among psoriasis biologics / Otezla, and which psoriasis agents do physicians and payers perceive to perform best on specific clinical and market access factors?
• How do payers cover biosimilar versions of infliximab (Pfizer’s Inflectra, Merck’s Renflexis), and what is physicians’ expected prescribing of biosimilars?
• What are physician perceptions of emerging therapies such as bimekizumab, Remsima (SC), and deucravacitinib and emerging nonsteroidal topical agents with novel mechanisms of action? How do payers anticipate covering these agents?
• What pharmacoeconomic models and data do payers value given the likely cost and efficacy of novel psoriasis agents?

PRODUCT DESCRIPTION

U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.

Key Drugs: Bimekizumab, Cimzia, Cosentyx, deucravacitinib, Enbrel, Humira, Ilumya, Inflectra, Otezla, Remicade, Remsima (SC), Renflexis, roflumilast (topical), Siliq, Skyrizi, Stelara, Tremfya, tapinarof.

Key Companies: AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB.